SciSparc Ltd. (Nasdaq: SPRC) subsidiary gains Japanese patent on novel pain treatment combo

Rhea-AI Filing Summary

SciSparc Ltd., through its majority-owned subsidiary NeuroThera Labs Inc., reports that the Japanese Patent Office has granted NeuroThera a patent titled “Compositions and Methods for Potentiating Derivatives of 4-Aminophenols.” The patent covers pharmaceutical compositions and methods using proprietary combinations of 4-aminophenol derivatives (including paracetamol) with N-acylethanolamines.

These combinations are designed to enhance the analgesic and antipyretic performance of 4-aminophenol-based therapies, which NeuroThera believes may allow lower effective dosing and help address dose-related side-effect concerns. The company states that this grant strengthens NeuroThera’s intellectual property portfolio and represents a strategic milestone as it advances combination-therapy platforms for pain, fever, and related conditions across global markets. SciSparc highlights its clinical-stage programs based on THC and non-psychoactive CBD, and NeuroThera’s broader focus on central nervous system and other underserved conditions.

Filing Explained

As a Form 6-K interim report, this filing furnishes the August 12 patent announcement and incorporates the report by reference into the listed F-3 and S-8 registration statements, subject to later supersession.

Key Figures

Patent jurisdiction: Japan Press release date: Aug. 12, 2026 Parent-subsidiary relationship: majority-owned

3 metrics

Patent jurisdiction Japan Japanese Patent Office granted a patent for NeuroThera’s pharmacological combination

Press release date Aug. 12, 2026 Date of announcement regarding the Japanese patent grant

Parent-subsidiary relationship majority-owned SciSparc engages in development through its majority-owned subsidiary NeuroThera

Key Terms

4-aminophenols, N-acylethanolamines, analgesic, antipyretic, +1 more

5 terms

4-aminophenols medical

"pharmacological combination titled “Compositions and Methods for Potentiating Derivatives of 4-Aminophenols.”"

N-acylethanolamines medical

"combinations of 4-aminophenols derivatives (including paracetamol) and N-acylethanolamines."

N-acylethanolamines are a family of naturally occurring fatty molecules that act as small chemical messengers inside the body, helping cells communicate about inflammation, appetite, pain and other processes. Investors care because these molecules can be targets or biomarkers for drugs, diagnostics and wellness products — like a visible readout on a dashboard that indicates whether a treatment is working or a condition is present — which affects clinical development, regulatory approval and market potential.

analgesic medical

"designed to enhance the analgesic and antipyretic performance of 4-aminophenol-based therapies."

An analgesic is a medication that reduces or eliminates pain without putting a person to sleep, covering common over-the-counter remedies through stronger prescription drugs. For investors, analgesics matter because their safety profile, regulatory approvals, patent protection and broad or limited use determine sales potential, liability exposure and long-term profits—think of them as either everyday household staples or specialized tools that drive revenue and risk.

antipyretic medical

"designed to enhance the analgesic and antipyretic performance of 4-aminophenol-based therapies."

A medication that lowers fever by reducing the body’s temperature, like a thermostat that brings an overheated system back toward normal. Investors care because antipyretics are common over‑the‑counter and prescription products whose safety profile, regulatory approvals, patent status and supply chain can affect a healthcare company’s sales, liability risk and growth prospects; changes in demand or regulation can influence stock value.

intellectual property portfolio regulatory

"This patent further strengthens NeuroThera’s expanding intellectual property portfolio reinforcing protection"

A collection of a company’s legally recognized creations and rights—such as patents, trademarks, copyrights, trade secrets and licensing agreements—that together protect its products, brands and technologies. Think of it as the company’s toolbox or recipe box: some items keep competitors out, some can be rented or sold, and some enable unique products. For investors, the breadth and strength of this portfolio affect future revenue potential, competitive position and legal risk, so it influences valuation and investment decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/12/2026 - 08:59 AM Accepted by SEC EDGAR 08/12/2026 - 08:58 AM Learn about SEC filing dates

FAQ

What did SciSparc Ltd. (SPRC) announce in this 6-K?

SciSparc reported that its majority-owned subsidiary NeuroThera Labs received a Japanese patent covering proprietary combinations of 4-aminophenol derivatives and N-acylethanolamines designed to enhance analgesic and antipyretic therapies.

What does the new Japanese patent cover for SciSparc’s subsidiary NeuroThera (SPRC)?

The patent covers pharmaceutical compositions and methods using proprietary combinations of 4-aminophenol derivatives (including paracetamol) with N-acylethanolamines intended to enhance pain- and fever-relief performance.

How could NeuroThera’s patented combinations benefit patients, according to SciSparc (SPRC)?

NeuroThera believes the combinations may enhance analgesic and antipyretic effects, potentially enabling lower effective doses and helping to address dose-related side-effect concerns of existing 4-aminophenol-based treatments.

Why is this Japanese patent strategically important for NeuroThera and SciSparc (SPRC)?

SciSparc states the grant strengthens NeuroThera’s intellectual property portfolio and marks a strategic milestone as it advances next-generation combination-therapy platforms for pain, fever, and related conditions in global markets.

What are SciSparc’s main drug development programs mentioned in the 6-K (SPRC)?

SciSparc, through NeuroThera, is developing SCI-110 for Tourette syndrome and Alzheimer’s-related agitation and SCI-210 for autism spectrum disorder and status epilepticus, based on THC and/or non-psychoactive CBD formulations.

Does SciSparc (SPRC) have any commercial activity besides clinical development?

Yes. Through NeuroThera, SciSparc holds a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace, alongside its clinical-stage pharmaceutical efforts.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of August 2026 (Report No. 2)

Commission File Number: 001-38041

SCISPARC LTD.

(Translation of registrant’s name into English)

20 Raul Wallenberg Street, Tower A,

Tel Aviv 6971916 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒     Form 40-F ☐

CONTENTS

On August 12, 2026, SciSparc Ltd. (the “Company”) issued a press release titled “SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination.” A copy of this press release is furnished herewith as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “Report”) and is incorporated by reference herein.

This Report is incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-248670, 333-255408, 333-293167 and 333-293533) and on Form S-8 (File Nos. 333-278437, 333-225773, 333-286791 and 333-292952) filed with the Securities and Exchange Commission to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

1

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press release issued by SciSparc Ltd. titled “SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination.”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SCISPARC LTD.
	By:	/s/ Oz Adler
	Name:	Oz Adler
	Title:	Chief Executive Officer and Chief Financial Officer

Date: August 12, 2026

3

Exhibit 99.1

 

SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination

TEL AVIV, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced that the Japanese Patent Office has granted the company a patent for NeuroThera’s pharmacological combination titled “Compositions and Methods for Potentiating Derivatives of 4-Aminophenols.”

The newly granted Japanese patent covers pharmaceutical compositions and methods comprising proprietary combinations of 4-aminophenols derivatives (including paracetamol) and N-acylethanolamines. These combinations are designed to enhance the analgesic and antipyretic performance of 4-aminophenol-based therapies. NeuroThera believes this synergistic approach may potentially enable lower effective dosing while helping to mitigate dose-related side-effect concerns associated with established treatments.

This patent further strengthens NeuroThera’s expanding intellectual property portfolio reinforcing protection for its combination-therapy platforms designed to optimize and modernize standard treatments for pain, fever, and related conditions.

The addition of Japanese patent coverage marks an important strategic milestone as NeuroThera advances its next-generation therapeutic innovations across global markets.

NeuroThera continues to advance its therapeutic platforms with the goal of delivering safe, effective, and accessible treatments to patients worldwide.

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

About NeuroThera Labs Inc.

NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the potential benefits of the patented combinations, including their potential to enhance the effects of 4-aminophenol derivatives, potentially enable lower effective doses and address dose-related side effects, as well as the potential for NeuroThera’s proprietary combination platforms to improve established therapies for pain, fever and related conditions and NeuroThera’s advancement of its next-generation therapeutic innovations across global markets and its goal of delivering safe, effective, and accessible treatments to patients worldwide. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE ISSUED BY SCISPARC LTD. TITLED "SCISPARC'S SUBSIDIARY NEUROTHERA L 8.0 KB